晚期NSCLC患者吉非替尼治疗前后血清CEA、CA125、CYFRA21-1、NSE水平变化及意义被引量：1

下载PDF

导出

摘要目的观察晚期非小细胞肺癌(NSCLC)患者吉非替尼治疗前后血清癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角质片段抗原(CYFRA21-1)及神经元特异性稀化醇(NSE)的水平变化,并探讨其意义。方法选择晚期NSCLC患者55例,均予吉非替尼治疗;分别于治疗前及治疗后2、4、6、8、12个月,检测血清CEA、CA125、CYFRA21-1、NSE水平。结果治疗2个月后,本组完全控制率(DSR)达74.55%;治疗2、4、6个月,血清CEA、CA125水平较治疗前逐渐降低(P均<0.05),而NSE、CYFRA21-1无明显变化(P均>0.05);治疗8个月时,血清CEA、CA125水平较治疗6个月时增加(P均<0.05);CEA>5 ng/mL患者的DCR为80.95%,高于<5 ng/mL者的53.85%(P<0.05)。结论晚期NSCLC患者吉非替尼治疗后较治疗前血清CEA、CA125水平明显降低,CYFRA21-1、NSE水平变化不明显;CEA检测有助于吉非替尼疗效的判断。

作者季学波黄正军耿立惠

机构地区沭阳县中心医院

出处《山东医药》 CAS 2012年第34期47-48,共2页 Shandong Medical Journal

关键词吉非替尼癌胚抗原糖类抗原125 细胞角质片段抗原神经元特异性稀化醇肺肿瘤非小细胞肺癌

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献10

1Li X, Asmitananda T, Gao L, et al. Biomarkers in the lung cancer diagnosis: a clinical perspective[J]. Neoplasma,2012, [Epub ahead of print].
2Joshi M, Jiang Y, Belani CP. Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuation [ J ]. Expert Opin Pharmacother, 2012,13 (5) :685-697.
3Assiddiq BF, Tan KY, Toy W, et al. EGFR Sl166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth[J]. J Proteome Res, 2012, [ Epub ahead of print].
4Zeng YD, Zhang L, Liao H, et al. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study [ J ]. Asian Pac J Cancer Prev,2012,13(3) :909-914.
5Tufman A, Huber RM. Biological markers in lung cancer: a clinician's perspective[J]. Cancer Biomark,2010,6(3-4) :123-135.
6Ebert W, Muley T, Drings P. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process [ J ]. Anticancer Res, 1996,16 (4B) : 2161-2168.
7Modi A, Vohra HA, Weeden DF. Does surgery for primary non- small cell lung cancer and cerebral metastasis have any impact on survival[ J ]. Interact Cardiovasc Thorac Surg, 2009,8 ( 4 ) : 467- 473.
8Xue X, Xue Q, Wang N, et al. Early clinical diagnosis of synchronous multiple primary lung cancer [ J ]. Oncol Lett, 2012,3 ( 1 ) :234-237.
9Edelman MJ, Hodgson L, Rosenblatt PY, et al. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective triM: CALGB 150304 [J]. J Thorac Oncol,2012,7 (4) :649-654.
10Chu XY, Hou XB, Song WA, et al. Diagnostic values of SCC, CEA, Cyfra21-1 and NSE for lung cancer in patients with suspicious pulmonary masses: a single center analysis [J]. Cancer Biol Ther,2011,11 (12) :995-1000.